ALK and non-small cell lung carcinoma: Previous studies conducted in ALK‐positive NSCLC revealed that pemetrexed‐based chemotherapy was more efficient than other regimens 13, which suggested that patients with ALK‐positive NSCLC may have a higher response rate with pemetrexed than does the general population with NSCLC 13, 17, 18.